The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

The ALK(F1174L) mutation is associated with intrinsic and acquired resistance to crizotinib and cosegregates with MYCN in neuroblastoma. In this study, we generated a mouse model overexpressing ALK(F1174L) in the neural crest. Compared to ALK(F1174L) and MYCN alone, co-expression of these two oncogenes led to the development of neuroblastomas with earlier onset, higher penetrance, and enhanced lethality. ALK(F1174L)/MYCN tumors exhibited increased MYCN dosage due to ALK(F1174L)-induced activation of the PI3K/AKT/mTOR and MAPK pathways, coupled with suppression of MYCN pro-apoptotic effects. Combined treatment with the ATP-competitive mTOR inhibitor Torin2 overcame the resistance of ALK(F1174L)/MYCN tumors to crizotinib. Our findings demonstrate a pathogenic role for ALK(F1174L) in neuroblastomas overexpressing MYCN and suggest a strategy for improving targeted therapy for ALK-positive neuroblastoma.

[1]  M. Brilliant,et al.  5' flanking sequences of the rat tyrosine hydroxylase gene target accurate tissue-specific, developmental, and transsynaptic expression in transgenic mice , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[2]  R. Palmer,et al.  Anaplastic lymphoma kinase: signalling in development and disease , 2009, The Biochemical journal.

[3]  L. Penn,et al.  Negative autoregulation of c‐myc transcription. , 1990, The EMBO journal.

[4]  R. Beijersbergen,et al.  Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. , 2009, Cancer cell.

[5]  Frank Speleman,et al.  Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification , 2010, Clinical Cancer Research.

[6]  Marc Ladanyi,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[7]  S. Evans,et al.  Surveillance, Epidemiology, and End Results (SEER) Database Analysis of Verrucous Carcinoma of the Vulva , 2012 .

[8]  A. Biankin,et al.  SIRT1 Promotes N-Myc Oncogenesis through a Positive Feedback Loop Involving the Effects of MKP3 and ERK on N-Myc Protein Stability , 2011, PLoS genetics.

[9]  D. Rowitch,et al.  Neuroblastoma Mycn Protein and Blocks Malignant Progression in Inhibition of Phosphatidylinositol 3-Kinase Destabilizes , 2006 .

[10]  I. Wierstra,et al.  The c-myc promoter: still MysterY and challenge. , 2008, Advances in cancer research.

[11]  Roberto Piva,et al.  The anaplastic lymphoma kinase in the pathogenesis of cancer , 2008, Nature Reviews Cancer.

[12]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.

[13]  C. Arvanitis,et al.  Conditional transgenic models define how MYC initiates and maintains tumorigenesis. , 2006, Seminars in cancer biology.

[14]  Shinji Yamazaki,et al.  Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.

[15]  Huaqing Zhao,et al.  Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma , 2011, Science Translational Medicine.

[16]  D. Neuberg,et al.  Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. , 2012, Cancer cell.

[17]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[18]  Y Taya,et al.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.

[19]  D. Sabatini,et al.  Mammalian Target of Rapamycin ( mTOR ) Inhibitor for Treatment of Cancer , 2011 .

[20]  G. Mohapatra,et al.  Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.

[21]  R. Palmer,et al.  Characterization of the expression of the ALK receptor tyrosine kinase in mice. , 2006, Gene expression patterns : GEP.

[22]  K. Matthay,et al.  Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma , 2012, Science Translational Medicine.

[23]  O. Perez,et al.  Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. , 2008, Cancer research.

[24]  Stella Pelengaris,et al.  c-MYC: more than just a matter of life and death , 2002, Nature Reviews Cancer.

[25]  K. Pulford,et al.  Anaplastic lymphoma kinase proteins in growth control and cancer , 2004, Journal of cellular physiology.

[26]  A. Peaston,et al.  Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Lowe,et al.  The p53–Bcl-2 connection , 2006, Cell Death and Differentiation.

[28]  K K Matthay,et al.  Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .

[29]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[30]  G. Evan,et al.  Distinct thresholds govern Myc's biological output in vivo. , 2008, Cancer cell.

[31]  J. Christensen,et al.  Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells , 2012, Oncogene.

[32]  William Pao,et al.  ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors , 2011, Clinical Cancer Research.

[33]  M. Saarma,et al.  Functional Characterization of Two Splice Variants of Rat Bad and Their Interaction with Bcl-w in Sympathetic Neurons , 2001, Molecular and Cellular Neuroscience.

[34]  G. Evan,et al.  The ups and downs of Myc biology. , 2010, Current opinion in genetics & development.

[35]  H. Sather,et al.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.

[36]  W. London,et al.  MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[38]  L. Tanoue,et al.  Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .

[39]  M. Hogarty,et al.  BH3 Response Profiles From Neuroblastoma Mitochondria Predict Activity of Small Molecule Bcl-2 Family Antagonists , 2009, Cell Death and Differentiation.

[40]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[41]  William C Hahn,et al.  The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. , 2005, Developmental cell.

[42]  Wei Zheng,et al.  The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. , 2010, Cancer research.

[43]  W. Weiss,et al.  Myc proteins as therapeutic targets , 2010, Oncogene.

[44]  J. Trent,et al.  Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc , 1984, Nature.